Sienna Biopharmaceuticals (NASDAQ:SNNA) issued its quarterly earnings results on Thursday. The company reported ($0.82) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.79) by ($0.03), MarketWatch Earnings reports.

NASDAQ SNNA traded down $0.52 during trading on Friday, reaching $10.05. 26,504 shares of the company’s stock were exchanged, compared to its average volume of 72,428. Sienna Biopharmaceuticals has a fifty-two week low of $8.77 and a fifty-two week high of $25.71. The firm has a market capitalization of $212.16 million, a PE ratio of -1.94 and a beta of 1.48. The company has a current ratio of 5.82, a quick ratio of 5.82 and a debt-to-equity ratio of 0.54.

A number of equities analysts recently weighed in on the company. BMO Capital Markets dropped their price target on Sienna Biopharmaceuticals from $30.00 to $27.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 1st. Zacks Investment Research cut Sienna Biopharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 3rd.

A hedge fund recently raised its stake in Sienna Biopharmaceuticals stock. Bank of New York Mellon Corp boosted its holdings in shares of Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) by 15.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 36,945 shares of the company’s stock after acquiring an additional 4,956 shares during the quarter. Bank of New York Mellon Corp owned 0.18% of Sienna Biopharmaceuticals worth $561,000 at the end of the most recent quarter. 47.46% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This news story was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.dailypolitical.com/2018/11/10/sienna-biopharmaceuticals-snna-announces-earnings-results-misses-estimates-by-0-03-eps.html.

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.

See Also: Preferred Stock

Earnings History for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.